|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.260 EUR | +0.42% |
|
-5.63% | -35.81% |
| 12-09 | Sources: Novo Nordisk Group Holding reduces stake in Evotec | DP |
| 12-09 | Evotec secondary ABB priced at EUR 5.10 per share, bookrunner says | RE |
| Capitalization | 929M 1.09B 867M 814M 1.5B 98.51B 1.64B 10.11B 3.93B 46.53B 4.1B 4.01B 170B | P/E ratio 2025 * |
-14.1x | P/E ratio 2026 * | -38.6x |
|---|---|---|---|---|---|
| Enterprise value | 1B 1.18B 937M 879M 1.63B 106B 1.77B 10.92B 4.24B 50.29B 4.43B 4.33B 183B | EV / Sales 2025 * |
1.29x | EV / Sales 2026 * | 1.24x |
| Free-Float |
88.77% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Evotec SE
| 1 day | +0.42% | ||
| 1 week | -5.63% | ||
| Current month | -9.31% | ||
| 1 month | +3.02% | ||
| 3 months | -9.90% | ||
| 6 months | -29.30% | ||
| Current year | -35.81% |
| 1 week | 4.9 |  | 5.53 |
| 1 month | 4.9 | | 5.89 |
| Current year | 4.9 | | 9.33 |
| 1 year | 4.9 | | 9.33 |
| 3 years | 4.9 | | 24.44 |
| 5 years | 4.9 | | 45.83 |
| 10 years | 2.86 | | 45.83 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 30/06/2024 | |
| Director of Finance/CFO | - | 28/02/2025 | |
Cord Dohrmann
CTO | Chief Tech/Sci/R&D Officer | 61 | 31/08/2010 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 65 | 14/06/2021 | |
Roland Sackers
BRD | Director/Board Member | 57 | 18/06/2019 |
| Director/Board Member | 63 | 31/05/2021 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 2.59% | 0 M€ | -.--% | - |
| 0.21% | 0 M€ | -.--% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.42% | -5.63% | -39.16% | -67.63% | 1.09B | |
| -2.53% | -4.41% | +0.34% | +14.63% | 46.35B | |
| +1.37% | +0.47% | +12.39% | +8.37% | 38.48B | |
| -0.57% | -3.19% | +74.01% | +62.86% | 35.5B | |
| +0.54% | +2.25% | +10.68% | +17.47% | 27.77B | |
| +0.96% | +3.92% | +65.78% | +175.14% | 15.95B | |
| +0.81% | +0.04% | +69.09% | +230.15% | 15.18B | |
| +2.19% | +2.24% | -10.49% | -2.48% | 14.5B | |
| -1.61% | -3.24% | +71.01% | - | 13.14B | |
| +0.65% | -3.26% | +108.32% | +111.04% | 12.82B | |
| Average | +0.29% | -1.16% | +36.20% | +61.06% | 22.08B | |
| Weighted average by Cap. | -0.18% | -1.10% | +34.61% | +54.50% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 781M 918M 729M 684M 1.27B 82.82B 1.38B 8.5B 3.3B 39.12B 3.45B 3.37B 143B | 840M 987M 784M 736M 1.36B 89.02B 1.48B 9.13B 3.55B 42.05B 3.7B 3.63B 153B |
| Net income | -77.33M -90.89M -72.2M -67.74M -125M -8.2B -136M -841M -327M -3.87B -341M -334M -14.11B | -28.16M -33.1M -26.29M -24.66M -45.61M -2.99B -49.65M -306M -119M -1.41B -124M -122M -5.14B |
| Net Debt | 74.9M 88.03M 69.93M 65.61M 121M 7.94B 132M 815M 317M 3.75B 330M 323M 13.67B | 111M 131M 104M 97.31M 180M 11.78B 196M 1.21B 470M 5.56B 490M 480M 20.27B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/12/25 | 5.240 € | +0.19% | 617,325 |
| 10/12/25 | 5.230 € | +2.47% | 864,954 |
| 09/12/25 | 5.104 € | -7.20% | 3,218,914 |
| 08/12/25 | 5.500 € | +1.36% | 535,732 |
| 05/12/25 | 5.426 € | -2.66% | 534,395 |
Delayed Quote Xetra, December 11, 2025 at 07:42 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- EVT Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition